Twice weekly 5-azacytidine infusion in disseminated metastatic cancer: A phase II study

Academic Article

Abstract

  • A phase II study of 5-azacytidine given twice weekly as a rapid iv infusion was performed on 116 patients with different metastatic cancers or refractory lymphomas at a dose of 150 mg/m2 twice weekly x 6. Ninety-one patients were evaluable. Dose modifications were carried out depending on previous treatment status. Nausea and vomiting was a major side effect; significant granulocytopenia was observed in 35 patients. Responses were observed in only 4 patients. The results indicate little effectiveness of this drug. The severe toxicity prevented escalation to potentially more effective dose levels.
  • Published In

    Author List

  • Velez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
  • Start Page

  • 1675
  • End Page

  • 1677
  • Volume

  • 61
  • Issue

  • 9